NCT02905864View on ClinicalTrials.gov

Liraglutide 3 mg for Knee Osteoarthritis

PHASE4CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

March 31, 2019

Conditions

OsteoarthritisObesity

Interventions

DRUG

Liraglutide 3 mg (Saxenda)

DRUG

Liraglutide 3 mg placebo

Trial Locations (1)

2000

Department of Rheumatology, Frederiksberg

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

collaborator

Cambridge Weight Plan Limited

INDUSTRY

lead

Henrik Gudbergsen

OTHER

NCT02905864 - Liraglutide 3 mg for Knee Osteoarthritis | Biotech Hunter | Biotech Hunter